The survivor-focused approach seeks mechanisms of resilience beyond traditional disease progression to identify novel therapeutic targets.

Under the agreement, Cure51 could receive up to €442 million per targeted opportunity in milestone payments, reflecting the program’s high potential.

Cure51’s model sequences tumor samples and integrates clinical histories to uncover actionable targets that could accelerate development of treatments for glioblastoma and other cancers.

Target selection will emphasize unmet needs, patient population defined by Servier, drug suitability, and target class, with initial priority targets disclosed to Servier for exploration and validation.

A new collaboration brings Cure51 together with Servier to translate survivor-derived biological insights into potential therapies for glioblastoma, leveraging Cure51’s data and Servier’s research capabilities.

This marks Cure51’s first research partnership with a pharmaceutical company and aligns with Servier’s focus on rare oncology and precision medicine, including brain tumour treatments.

Using Cure51’s survivor-focused database and computational platform alongside Servier’s R&D strength, the partners aim to identify new glioblastoma targets and therapeutic opportunities.

Glioblastoma is the most common and aggressive primary malignant brain tumour in adults, with median survival of 12–18 months and notable heterogeneity and blood–brain barrier challenges; a minority survives beyond five years.

The disease’s aggressiveness remains a major hurdle, though a subset of patients can achieve long-term survival.

Cure51’s work spans glioblastoma as well as pancreatic and small-cell lung cancers, reflecting a broader focus on ultra-aggressive cancers.

Cure51 founder Nicolas Wolikow notes the company processes vast data—reportedly over a terabyte per patient—to derive actionable insights.

Cure51 studies exceptional survivors from a global network of more than 150 oncology centres in 38 countries, collecting clinical data and tissue samples to illuminate resilience mechanisms via molecular sequencing.